Michael Altaweel is an Ophthalmology physician affiliated with University of Wisconsin–Madison. OpenAlex indexes 120 publications with 4,651 citations (h-index 30); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2880 University Ave
Madison, WI 53705
Telephone
608-263-9339Provider last certified this registry record 12 Jan 2021.
Clinical trials
- Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Sponsor: University of Wisconsin, Madison
- Bevacizumab Against Recurrent Retinal Detachment
Sponsor: University of Wisconsin, Madison
- Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects
Sponsor: University of Wisconsin, Madison
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20251 payment
- Apellis Pharmaceuticals, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
80.6%Corticosteroid21.8%Prednisolone Acetate100%Part D≥43 patientsCarbonic Anhydrase Inhibitor18%Dorzolamide-Timolol57%Dorzolamide Hcl43%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
14.5%Cyclooxygenase Inhibitor14.5%Ketorolac Tromethamine100%Part D≥18 patientsCardiovascular
4.8%Beta blocker4.8%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2004–2022 per NIH RePORTER. The latest:
- ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
University of Wisconsin-Madison
FY2022$282,710UG1EY028087 - ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
University of Wisconsin-Madison
FY2021$282,710UG1EY028087 - ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
University of Wisconsin-Madison
FY2020$282,709UG1EY028087
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
William Busse, MD
University of Wisconsin–Madison
David Andes, MD
University of Wisconsin–Madison
Neil Binkley, MD
University of Wisconsin–Madison
Robert Lemanske, MD
University of Wisconsin–Madison
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”